Ventas (VTR)
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-10-30
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-10-30
Research Workspace
Put VTR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Real Estate is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — SHOP Same-Store Cash NOI growth > 15% YoY: Direct metric needs a verified mapping.
View ThesisRevenue growth is accelerating — up about 22% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 34%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 60% growth a year, above the roughly 11% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskVTR's SHOP investment must sustain growth because recent financial performance is weak and its earnings yield trails the sector. Recent revenue growth slowed from 22% to 21%; Q3 2026 headlines report an EPS miss. The company trades at 24× P/FFO versus a 12× peer median. The market prices in more growth than our forecast. The risk is that this premium compresses if growth disappoints. A 27% next-quarter miss probability adds earnings risk. peer multiples imply a price about 60% below where it trades. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. VTR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 24 analysts currently covering VTR (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for VTR in the last 4 months.
Continue this research
Compare VTR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VTR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care REITs — fair value, gap to price, and forward P/E.
Compare the value case
Put VTR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase full-year earnings guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $84.80
The last 12 months of price, then the range of analyst 12-month targets from today’s $84.80.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
2026 FFO outlook and $5.2B of closed SHOP investments support earnings growth and exceed the $4.5B target.

Advances: Deliver SHOP Same-Store Cash NOI growth
Q3 earnings call is a material source for SHOP same-store NOI and guidance progress, though details are unspecified.

Advances: Expand senior housing investments to $4.5 billion in 2026
Confirms investment expansion and raises earnings guidance.

Advances: Increase full year 2026 earnings guidance
Earnings call supports guidance increase for 2026.

Threatens: Drive Same-Store Cash NOI growth in Senior Housing Operating Portfolio
Shares fell despite strong SHOP NOI growth.

Surpassing estimates indicates strong operational performance.